Anbio Biotechnology (NNNN) stock
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$3.60−0.05 (-1.37%)
Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –
Anbio Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $5.77M, up 189.1% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.77M | +189.1% |
| FY2024 | Dec 31, 2024 | $2.00M | +1.8% |
| FY2023 | Dec 31, 2023 | $1.96M | -80.8% |
| FY2022 | Dec 31, 2022 | $10.20M | – |
See a number that looks wrong?